Lan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lan Wang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Hong Wang2 shared publications
- Jing Liu
Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing Key Laboratory for Big Data Innovative Application of Child and Adolescent Mental Disorders, Beijing, China
2 shared publications - Li Sun
Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China
2 shared publications - Minglong Gao2 shared publications
- Qingjiu Cao
Peking University Sixth Hospital Beijing China
2 shared publications - Wenting Lu2 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e103430
Smartphone-Delivered Cognitive Behavioral Digital Therapeutic for Children and Adolescents With Major Depressive Disorder: Protocol for a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Background: Depression is a leading contributor to morbidity and disability in children and adolescents. Cognitive behavioral therapy (CBT) is a guideline-recommended first-line treatment, but access is constrained by therapist supply, distance, and stigma. Internet-based CBT is a scalable adjunct in adults, yet regulatory-grade evidence in Chinese pediatric samples remains limited. Objective: This trial will determine whether a smartphone-delivered CBT-based digital therapeutic is superior to a matched health-education placebo in reducing depressive symptoms in Chinese children and adolescents with major depressive disorder (MDD), and characterize its safety. Methods: This is a prospective, multicenter, double-blind, placebo-controlled superiority trial at 4 tertiary-A hospitals in mainland China. Children and adolescents aged 8-17 years meeting DSM-5 (Diagnostic and Statistical Manual of Mental Disorders [Fifth Edition]) criteria for current MDD without psychotic features and scoring above 30 on the Children’s Depression Rating Scale-Revised (CDRS-R) at screening will be randomized 1:1 to the investigational digital therapeutic (Model WL-PD) or a visually matched health-education placebo. Both arms receive 8 weeks of structured content on an identical schedule; participants with CDRS-R ≥57 additionally receive open-label fluoxetine under weight-banded dosing. The primary end point is CDRS-R total-score reduction from baseline to week 8. Secondary end points include CDRS-R change at weeks 1 to 6; response and remission rates; Clinical Global Impression scores; the Children’s Depression Inventory; the Conners’ Parent Symptom Questionnaire; and a week-8 device-performance evaluation. Safety end points include adverse-event, serious adverse-event, and device-defect incidence. The planned sample of 214 participants (107 per arm) is powered at 80% to detect a between-arm difference of 4.6 CDRS-R points (assumed control SD 10.7) with a 1-sided α of .025 and 20% inflation for attrition. The primary analysis is an analysis of covariance on the full analysis set adjusting for baseline CDRS-R, severity category, fluoxetine exposure, and site; superiority is declared if the lower bound of the 2-sided 95% CI excludes zero, with a mixed model for repeated measures as a sensitivity analysis. Results: The trial opened to enrollment in March 2026; recruitment is ongoing, with a planned close in December 2026. The last week-8 visit is expected in the first quarter of 2027, and the primary analysis the following year. Conclusions: The trial addresses 3 recognized gaps in the pediatric digital therapeutics literature: a rigorous, structurally matched blinded control condition, recruitment beyond a single site, and integration of guideline-concordant pharmacotherapy. Because recruitment is confined to tertiary hospitals and excludes participants with prominent suicidality or comorbidity, findings will apply to supervised use in specialist services rather than unselected community care. Trial Registration: Chinese Clinical Trial Registry ChiCTR2600120453; https://tinyurl.com/3xzaajhp International Registered Report Identifier (IRRID): DERR1-10.2196/103430
- 13 November 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e103430
Open AccessSmartphone-Delivered Cognitive Behavioral Digital Therapeutic for Children and Adolescents With Major Depressive Disorder: Protocol for a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Background: Depression is a leading contributor to morbidity and disability in children and adolescents. Cognitive behavioral therapy (CBT) is a guideline-recommended first-line treatment, but access is constrained by therapist supply, distance, and stigma. Internet-based CBT is a scalable adjunct in adults, yet regulatory-grade evidence in Chinese pediatric samples remains limited. Objective: This trial will determine whether a smartphone-delivered CBT-based digital therapeutic is superior to a matched health-education placebo in reducing depressive symptoms in Chinese children and adolescents with major depressive disorder (MDD), and characterize its safety. Methods: This is a prospective, multicenter, double-blind, placebo-controlled superiority trial at 4 tertiary-A hospitals in mainland China. Children and adolescents aged 8-17 years meeting DSM-5 (Diagnostic and Statistical Manual of Mental Disorders [Fifth Edition]) criteria for current MDD without psychotic features and scoring above 30 on the Children’s Depression Rating Scale-Revised (CDRS-R) at screening will be randomized 1:1 to the investigational digital therapeutic (Model WL-PD) or a visually matched health-education placebo. Both arms receive 8 weeks of structured content on an identical schedule; participants with CDRS-R ≥57 additionally receive open-label fluoxetine under weight-banded dosing. The primary end point is CDRS-R total-score reduction from baseline to week 8. Secondary end points include CDRS-R change at weeks 1 to 6; response and remission rates; Clinical Global Impression scores; the Children’s Depression Inventory; the Conners’ Parent Symptom Questionnaire; and a week-8 device-performance evaluation. Safety end points include adverse-event, serious adverse-event, and device-defect incidence. The planned sample of 214 participants (107 per arm) is powered at 80% to detect a between-arm difference of 4.6 CDRS-R points (assumed control SD 10.7) with a 1-sided α of .025 and 20% inflation for attrition. The primary analysis is an analysis of covariance on the full analysis set adjusting for baseline CDRS-R, severity category, fluoxetine exposure, and site; superiority is declared if the lower bound of the 2-sided 95% CI excludes zero, with a mixed model for repeated measures as a sensitivity analysis. Results: The trial opened to enrollment in March 2026; recruitment is ongoing, with a planned close in December 2026. The last week-8 visit is expected in the first quarter of 2027, and the primary analysis the following year. Conclusions: The trial addresses 3 recognized gaps in the pediatric digital therapeutics literature: a rigorous, structurally matched blinded control condition, recruitment beyond a single site, and integration of guideline-concordant pharmacotherapy. Because recruitment is confined to tertiary hospitals and excludes participants with prominent suicidality or comorbidity, findings will apply to supervised use in specialist services rather than unselected community care. Trial Registration: Chinese Clinical Trial Registry ChiCTR2600120453; https://tinyurl.com/3xzaajhp International Registered Report Identifier (IRRID): DERR1-10.2196/103430
- Open Access
- 3 June 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Smartphone-Delivered Cognitive Behavioral Digital Therapeutic for Children and Adolescents With Major Depressive Disorder: Protocol for a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (Preprint)
BACKGROUND Depression is a leading contributor to morbidity and disability in children and adolescents. Cognitive behavioral therapy (CBT) is a guideline-recommended first-line treatment, but access is constrained by therapist supply, distance, and stigma. Internet-based CBT is a scalable adjunct in adults, yet regulatory-grade evidence in Chinese pediatric samples remains limited. OBJECTIVE This trial will determine whether a smartphone-delivered CBT-based digital therapeutic is superior to a matched health-education placebo in reducing depressive symptoms in Chinese children and adolescents with major depressive disorder (MDD), and characterize its safety. METHODS This is a prospective, multicenter, double-blind, placebo-controlled superiority trial at 4 tertiary-A hospitals in mainland China. Children and adolescents aged 8-17 years meeting DSM-5 (Diagnostic and Statistical Manual of Mental Disorders [Fifth Edition]) criteria for current MDD without psychotic features and scoring above 30 on the Children’s Depression Rating Scale-Revised (CDRS-R) at screening will be randomized 1:1 to the investigational digital therapeutic (Model WL-PD) or a visually matched health-education placebo. Both arms receive 8 weeks of structured content on an identical schedule; participants with CDRS-R ≥57 additionally receive open-label fluoxetine under weight-banded dosing. The primary end point is CDRS-R total-score reduction from baseline to week 8. Secondary end points include CDRS-R change at weeks 1 to 6; response and remission rates; Clinical Global Impression scores; the Children’s Depression Inventory; the Conners’ Parent Symptom Questionnaire; and a week-8 device-performance evaluation. Safety end points include adverse-event, serious adverse-event, and device-defect incidence. The planned sample of 214 participants (107 per arm) is powered at 80% to detect a between-arm difference of 4.6 CDRS-R points (assumed control SD 10.7) with a 1-sided α of .025 and 20% inflation for attrition. The primary analysis is an analysis of covariance on the full analysis set adjusting for baseline CDRS-R, severity category, fluoxetine exposure, and site; superiority is declared if the lower bound of the 2-sided 95% CI excludes zero, with a mixed model for repeated measures as a sensitivity analysis. RESULTS The trial opened to enrollment in March 2026; recruitment is ongoing, with a planned close in December 2026. The last week-8 visit is expected in the first quarter of 2027, and the primary analysis the following year. CONCLUSIONS The trial addresses 3 recognized gaps in the pediatric digital therapeutics literature: a rigorous, structurally matched blinded control condition, recruitment beyond a single site, and integration of guideline-concordant pharmacotherapy. Because recruitment is confined to tertiary hospitals and excludes participants with prominent suicidality or comorbidity, findings will apply to supervised use in specialist services rather than unselected community care. CLINICALTRIAL Chinese Clinical Trial Registry ChiCTR2600120453; https://tinyurl.com/3xzaajhp INTERNATIONAL REGISTERED REPORT DERR1-10.2196/103430
- 3 June 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessSmartphone-Delivered Cognitive Behavioral Digital Therapeutic for Children and Adolescents With Major Depressive Disorder: Protocol for a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (Preprint)
BACKGROUND Depression is a leading contributor to morbidity and disability in children and adolescents. Cognitive behavioral therapy (CBT) is a guideline-recommended first-line treatment, but access is constrained by therapist supply, distance, and stigma. Internet-based CBT is a scalable adjunct in adults, yet regulatory-grade evidence in Chinese pediatric samples remains limited. OBJECTIVE This trial will determine whether a smartphone-delivered CBT-based digital therapeutic is superior to a matched health-education placebo in reducing depressive symptoms in Chinese children and adolescents with major depressive disorder (MDD), and characterize its safety. METHODS This is a prospective, multicenter, double-blind, placebo-controlled superiority trial at 4 tertiary-A hospitals in mainland China. Children and adolescents aged 8-17 years meeting DSM-5 (Diagnostic and Statistical Manual of Mental Disorders [Fifth Edition]) criteria for current MDD without psychotic features and scoring above 30 on the Children’s Depression Rating Scale-Revised (CDRS-R) at screening will be randomized 1:1 to the investigational digital therapeutic (Model WL-PD) or a visually matched health-education placebo. Both arms receive 8 weeks of structured content on an identical schedule; participants with CDRS-R ≥57 additionally receive open-label fluoxetine under weight-banded dosing. The primary end point is CDRS-R total-score reduction from baseline to week 8. Secondary end points include CDRS-R change at weeks 1 to 6; response and remission rates; Clinical Global Impression scores; the Children’s Depression Inventory; the Conners’ Parent Symptom Questionnaire; and a week-8 device-performance evaluation. Safety end points include adverse-event, serious adverse-event, and device-defect incidence. The planned sample of 214 participants (107 per arm) is powered at 80% to detect a between-arm difference of 4.6 CDRS-R points (assumed control SD 10.7) with a 1-sided α of .025 and 20% inflation for attrition. The primary analysis is an analysis of covariance on the full analysis set adjusting for baseline CDRS-R, severity category, fluoxetine exposure, and site; superiority is declared if the lower bound of the 2-sided 95% CI excludes zero, with a mixed model for repeated measures as a sensitivity analysis. RESULTS The trial opened to enrollment in March 2026; recruitment is ongoing, with a planned close in December 2026. The last week-8 visit is expected in the first quarter of 2027, and the primary analysis the following year. CONCLUSIONS The trial addresses 3 recognized gaps in the pediatric digital therapeutics literature: a rigorous, structurally matched blinded control condition, recruitment beyond a single site, and integration of guideline-concordant pharmacotherapy. Because recruitment is confined to tertiary hospitals and excludes participants with prominent suicidality or comorbidity, findings will apply to supervised use in specialist services rather than unselected community care. CLINICALTRIAL Chinese Clinical Trial Registry ChiCTR2600120453; https://tinyurl.com/3xzaajhp INTERNATIONAL REGISTERED REPORT DERR1-10.2196/103430
- Open Access
- 29 April 2022
- Published by Springer Nature in Translational Psychiatry
- Vol. 12 (1) , 1-7
Prenatal earthquake stress exposure in different gestational trimesters is associated with methylation changes in the glucocorticoid receptor gene (NR3C1) and long-term working memory in adulthood
Prenatal stress exposure is thought to affect the long-term development of the foetal brain via the HPA axis and to change health outcomes in adulthood, including working memory (WM). The potential mechanism is that there is a critical period of brain development of the foetus, which is a result of selective adaptation to the external environment. The human glucocorticoid gene (NR3C1) is associated with memory and cognition. This study investigates the association between earthquake stress during pregnancy and CpG methylation of the NR3C1 exon 1Fpromoter and its influence on working memory in adulthood. DNA methylation analysis using bisulfite sequencing PCR was quantified in 176 subjects who were exposed or not exposed to intrauterine earthquake and were divided into three groups based on the pregnancy trimester. The Hopkins Verbal Learning Test-Revised (HVLT-R) and Brief Visuospatial Memory Test-Revised (BVMT-R) were used to assess working memory performance. The methylated NR3C1 exon 1Fpromoter of the prenatal earthquake exposure (PEE) group was significantly higher than that of the control group (CN). Analysis of subgroups indicated that the subjects in the second trimester of PEE group showed significantly higher methylation than those in the third trimester. Significantly low BVMT-R scores were detected in those who experienced prenatal earthquake in the second trimester of PEE group. Methylated CpG site 1 may play a critical role in contributing to lower BVMT-R scores in the second trimester in the PEE group, and may offer a potential epigenetic mechanism that links prenatal stress and long-term effects on working memory.
- 29 April 2022
- Published by Springer Nature in Translational Psychiatry
- Vol. 12 (1) , 1-7
Open AccessPrenatal earthquake stress exposure in different gestational trimesters is associated with methylation changes in the glucocorticoid receptor gene (NR3C1) and long-term working memory in adulthood
Prenatal stress exposure is thought to affect the long-term development of the foetal brain via the HPA axis and to change health outcomes in adulthood, including working memory (WM). The potential mechanism is that there is a critical period of brain development of the foetus, which is a result of selective adaptation to the external environment. The human glucocorticoid gene (NR3C1) is associated with memory and cognition. This study investigates the association between earthquake stress during pregnancy and CpG methylation of the NR3C1 exon 1Fpromoter and its influence on working memory in adulthood. DNA methylation analysis using bisulfite sequencing PCR was quantified in 176 subjects who were exposed or not exposed to intrauterine earthquake and were divided into three groups based on the pregnancy trimester. The Hopkins Verbal Learning Test-Revised (HVLT-R) and Brief Visuospatial Memory Test-Revised (BVMT-R) were used to assess working memory performance. The methylated NR3C1 exon 1Fpromoter of the prenatal earthquake exposure (PEE) group was significantly higher than that of the control group (CN). Analysis of subgroups indicated that the subjects in the second trimester of PEE group showed significantly higher methylation than those in the third trimester. Significantly low BVMT-R scores were detected in those who experienced prenatal earthquake in the second trimester of PEE group. Methylated CpG site 1 may play a critical role in contributing to lower BVMT-R scores in the second trimester in the PEE group, and may offer a potential epigenetic mechanism that links prenatal stress and long-term effects on working memory.